NCT01451580Unknown2 期
A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer
TTY Biopharm1 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2005年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 47
- 试验地点
- 1
研究概览
简要总结
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically proved breast cancer with metastatic disease
排除标准
- •life expectancy less than 3 months.
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT01051362The First Affiliated Hospital of Guangzhou Medical University48
进行中（未招募）
不适用
Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy - AROBASEBreast Cancer Patients with Brain MetastasesMedDRA version: 9.1Level: PTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-006790-81-FRAPREC50
Unknown
2 期
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00742404Oncotherapeutics35
进行中（未招募）
不适用
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsGynecologic Sarcomas and Mixed Epithelial-Mesenchymal TumorsEUCTR2008-000245-55-DEGYN Research GmbH
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43